SMMT Earnings Results and History
Summit Therapeutics Inc.'s earnings at a glance: the latest results and outlook from the press release, revenue, margins and EPS for every quarter from the company's SEC filings, and how the stock moved after each report. New results show here within about a minute of being filed.
- Adjusted EPS−$0.20 vs −$0.28 est +29.0%
- GAAP EPS−$0.26
- Revenue– vs $72K est
Filed ยท Press release
Key takeaways
AI summary of the press release- GAAP net loss was $208.4M, or $0.26 per share, versus $231.8M or $0.31 a year earlier, aided by lower stock compensation.
- Non-GAAP operating expenses rose to $166.9M from $103.4M as ivonescimab clinical study and development costs expanded.
Reports and price reactions
last 1 reportsFilings and dates
SEC EDGAR- Nov 9, 2026Next earnings reportexpected
- Nov 4, 2026Earnings release, Q3 20268-K Press release
Also see SMMT institutional ownership and the earnings calendar.
SMMT earnings FAQ
What were SMMT's latest earnings?
For Q3 2026 Summit Therapeutics Inc. reported, GAAP EPS of -$0.26 and adjusted EPS of -$0.20. The results were filed with the SEC on Nov 4, 2026.
When is SMMT's next earnings date?
Summit Therapeutics Inc. is expected to report on Nov 9, 2026. Dates can move until the company confirms them.
Where do these numbers come from?
Results, guidance and financials come from Summit Therapeutics Inc.'s own SEC filings: the earnings press release (Form 8-K) and the quarterly and annual reports (10-Q and 10-K). Key takeaways are an AI summary of the press release. Estimates and price moves come from market data.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Results come from company filings with the SEC. Estimates are consensus figures from before each report. Key takeaways are an AI summary of the company's press release and may contain errors; the press release is the authoritative source.